Viscera Technologies Ltd Competitors

Sonic Incytes is committed to enhancing patient care through innovative diagnostic solutions. The company's flagship product, Velacur™, equips physicians with an advanced liver imaging tool to help manage the growing epidemic of fatty liver disease. Velacur offers real-time, AI guided quantification of the two key markers for fatty liver disease: liver stiffness and attenuation. With real-time results, a low up-front cost and AI guidance, VELACUR makes liver imaging at the point of care affordable and accessible.

CardiAI is a data-driven company that harnesses technical innovation to create positive outcomes for patients. CardiAI is creating a handheld medical device that can rapidly diagnose, manage and monitor infectious diseases and chronic health conditions. We have a team of dedicated scientists, clinical researchers and hardware developers who work together to develop rapid diagnostic tools. CardiAi has created a point-of-care device to detect Covid-19 and biomarkers for other chronic diseases. Patients can use the device to test themselves and send the results to their physician. The physician then has all the information they need to deliver highly personalized care. The device is part of a technology platform that uses data and analytics to enhance patient care. Advanced analytics powered by machine learning can provide insights for patients, healthcare providers and insurance companies and drives the health care system towards integration. CardiAI’s machine learning and data processing allows for fast and efficient prediction models by leveraging historical and real time data. With CardiAI’s data collection and analytics platform, healthcare service providers can make better decisions for a patient’s diagnosis and treatment.

Cardio-HART by Cardio Phoenix is the first cardiac diagnostic system that combines the diagnostic functionality of an 1) AI reporting 12 Lead ECG, 2) Phonocardiograph, and 3) Echocardiograph. * Detects 14 significant cardiac abnormalities, typically only diagnosed by Echocardiography. * Detects Heart Failure: HFpEF, HFmrEF, HFrEF, and LVEF % * Quick | Non-invasive | Provides Immediate Results The main focus of this project is to provide an integrated CVD patient pathway to cover initial disease detection in Primary Care through diagnosis confirmation and treatment in Secondary Care specialists & cardiology services. By using an innovative digitally enabled and AI-assisted technology (Cardio-HART) there is the opportunity to provide essential diagnostic information to Health Care Professionals and transform the patient pathway to improve early CVD detection.